Characterization of invasive meningococcal disease case isolates in Atlantic Canada, 2014 to 2020: spatial–temporal variations of clones and predicted meningococcal B vaccine coverage

References

1. Tsang RSW, Law DKS, De Paola R, Giuliani M, Stella M et al. Culture-confirmed invasive meningococcal disease in Canada, 2010 to 2014: characterization of serogroup B Neisseria meningitidis strains and their predicted coverage by the 4CMenB vaccine. mSphere 2020; 5:e00883-19 [View Article]
   [Google Scholar]
2. De Wals P. Epidemiology and control of meningococcal disease in Canada: a long, complex, and unfinished story. Can J Infect Dis Med Microbiol 2019; 2019:8901847 [View Article]
   [Google Scholar]
3. Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci 2006; 103:10834–10839 [View Article]
   [Google Scholar]
4. Pillai S, Howell A, Alexander K, Bentley BE, Jiang H-Q et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 2005; 23:2206–2209 [View Article] [PubMed]
   [Google Scholar]
5. Public Health Agency of Canada The recommended use of the multicomponent meningococcal B (4CMenB) vaccine in Canada: common guidance statement; 2014Mar26 https://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-103-2014-eng.pdf
6. Harrison R, Stirling R, Baclic O, Vaudry W. Summary of the NACI statement on the use of bivalent factor H binding protein meningococcal serogroup B (MenB-fHBP) vaccine for the prevention of meningococcal B disease. Can Commun Dis Rep 2020; 46:36–39 [View Article]
   [Google Scholar]
7. Tsang RSW, Law DKS, Gad RR, Mailman T, German G et al. Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A). Can J Infect Dis Med Microbiol 2015; 26:299–304 [View Article] [PubMed]
   [Google Scholar]
8. Statistics Canada Canada population estimates, quarterly. Statistics Canada, The Government of Canada. (accessed on April 1, 2022); 2022 https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000901&cubeTimeFrame.startMonth=01&cubeTimeFrame.startYear=2014&cubeTimeFrame.endMonth=10&cubeTimeFrame.endYear=2020&referencePeriods=20140101%2C20201001
9. Zhou J, Lefebvre B, Deng S, Gilca R, Deceuninck G et al. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol 2012; 50:1545–1551 [View Article] [PubMed]
   [Google Scholar]
10. Law DKS, Lorange M, Ringuette L, Dion R, Giguère M et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006; 44:2743–2749 [View Article] [PubMed]
    [Google Scholar]
11. Maiden MCJ, Bygraves JA, Feil E, Morelli G, Russell JE et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci 1998; 95:3140–3145 [View Article]
    [Google Scholar]
12. Lucidarme J, Hill DMC, Bratcher HB, Gray SJ, du Plessis M et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect 2015; 71:544–552 [View Article]
    [Google Scholar]
13. Vogel U, Claus H, Frosch M, Caugant DA. Molecular basis for distinction of the ET-15 clone within the ET-37 complex of Neisseria meningitidis. J Clin Microbiol 2000; 38:941–942 [View Article]
    [Google Scholar]
14. Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R et al. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS One 2012; 7:1–9 [View Article] [PubMed]
    [Google Scholar]
15. Matthews TC, Bristow FR, Griffiths EJ, Petkau A, Adam J et al. The integrated rapid infectious disease analysis (IRIDA) platform. Bioinformatics 2018 [View Article]
    [Google Scholar]
16. Jolley KA, Maiden MCJ. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 2010; 11:595 [View Article]
    [Google Scholar]
17. Brehony C, Rodrigues CMC, Borrow R, Smith A, Cunney R et al. Distribution of Bexsero® antigen sequence types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. Vaccine 2016; 34:4690–4697 [View Article]
    [Google Scholar]
18. Muzzi A, Brozzi A, Serino L, Bodini M, Abad R et al. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine 2019; 37:991–1000 [View Article]
    [Google Scholar]
19. Rodrigues CMC, Jolley KA, Smith A, Cameron JC, Feavers IM et al. Meningococcal deduced vaccine antigen reactivity (MenDeVAR) index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J Clin Microbiol 2020; 59:e02161–e02173 [View Article]
    [Google Scholar]
20. Tsang R, Hoang L, Tyrrell GJ, Horsman G, Van Caeseele P et al. Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009-2016. Can Commun Dis Rep 2017; 43:144–149 [View Article]
    [Google Scholar]
21. Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother 2019; 15:470–480 [View Article] [PubMed]
    [Google Scholar]
22. Taha M-K, Deghmane A-E, Knol M, van der Ende A. Whole genome sequencing reveals Trans-European spread of an epidemic Neisseria meningitidis serogroup W clone. Clin Microbiol Infect 2019; 25:765–767 [View Article] [PubMed]
    [Google Scholar]